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HUMAN TUMOR STEM-CELL ASSAY 
To tile Editor: Since our group first reported on the potential clini­
cal applications of the human tumor stem-cell, or clonogcnic, assay 
in the journal, 1 we think some comment from us is warranted regard­
ing the recent article by Sdby ct al.i and the editorial by Von Hoff.:1 
We dearly agree that it is important to plate good single-cell sus­
pensions, that drug-sensitivity critcri,1 arc still in the developmental 
stages,'1 that some drugs may require the evaluation of various expo­
sure times, that inappropriate drug concentrations may be mislead­
ing, that drugs requiring bioactivation present special problems, 
that radiation-survival curves with plateaus at high dosage prob­
ably represen t artifacts, that individual tumor types need special 
effort in assay development, and that clinical-response criteria, such 
as thr partial response, may not translate into a survival advantage. 
All these faciors arc subjects of ongoing rcs1·arch. Complete remis­
sion, prolonged survival, and cure will eventually prove to he better 
benchmarks for clinical n,rrrlation of drug dli-cts in vitro.�' A rrrrnt 
review of clinical evaluations in over 450 patients studierl in various 
institutions'; supports the clinical potential of chemosensitivity test­
ing in certain typrs of tumor and clocumrnts that the assay can 
identify chcmoscnsitivc patiems. We don't think tllilt the assay sys­
tem is ready for routine clinical use. Currently, its application to 
ovarian cancer in relapse appears particularly promising. 7 How­
ever, donogcnic assay procedures cannot be expected to improve 
the clinical response to drugs markedly as long as availahk clrngs 
arc rel a lively ineffoctivc. 
Principally, on the hasis of theoretical constructs, Selby ct al.i 
prnviclcd their perspectives on clonal assays, assuming a hierarchi­
cal morlcl of tumor stem-cell dilfcrcntiation. 'l'his mnclr.l will also 
require critical testing and clinical correlation. 
We agree with Von Hoff" that rt•s1·arch on tumor cloning obvi­
ously should he viewed as evolutionary rather than as a complctrd 
construct requiring immediate acceptance or rejection. The scope of 
research involving in vitro studies of human tumors and investiga­
tions of their applicability to chemoscnsitivity testing is greater now 
than we would have predicted at the time of the first report in the 
Journal five years ago. 
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